Studies demonstrate that HIF2α can potentiate MYC transcriptional activity and that MYC gene signatures are able to define a subtype of ccRCC, while HIF1α has the potential to oppose MYC transcriptional activity18, 19, 20. This evidence concerns the gene HIF1A and nonpapillary renal cell carcinoma.